These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P; Königs C Blood; 2017 Aug; 130(6):808-816. PubMed ID: 28507083 [TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693 [TBL] [Abstract][Full Text] [Related]
7. The humoral response to human factor VIII in hemophilia A mice. Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826 [TBL] [Abstract][Full Text] [Related]
8. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272 [TBL] [Abstract][Full Text] [Related]
9. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535 [TBL] [Abstract][Full Text] [Related]
10. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P Thromb Haemost; 2009 Jul; 102(1):35-41. PubMed ID: 19572065 [TBL] [Abstract][Full Text] [Related]
11. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor. Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716 [TBL] [Abstract][Full Text] [Related]
12. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors. Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758 [TBL] [Abstract][Full Text] [Related]
13. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641 [TBL] [Abstract][Full Text] [Related]
14. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates. Di Giambattista M; Branckaert T; Hougardy V; Kemball-Cook G; Laub R Mol Immunol; 2007 Mar; 44(8):1903-13. PubMed ID: 17113150 [TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850 [TBL] [Abstract][Full Text] [Related]
16. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Reding MT; Lei S; Lei H; Green D; Gill J; Conti-Fine BM Thromb Haemost; 2002 Oct; 88(4):568-75. PubMed ID: 12362225 [TBL] [Abstract][Full Text] [Related]
17. Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity. Mizumachi K; Nakajima Y; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K Haemophilia; 2024 Jan; 30(1):140-150. PubMed ID: 38058226 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758 [TBL] [Abstract][Full Text] [Related]
19. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors. van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984 [TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]